New combo therapy tested for rare blood cancers
NCT ID NCT02493530
First seen May 20, 2026 · Last updated May 20, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug (TGR-1202) combined with a standard drug (ruxolitinib) in 60 people with myelofibrosis or polycythemia vera that stopped responding to usual treatment. The main goal was to check safety and find the right dose. Researchers also looked for signs that the combo might help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic - Arizona
Phoenix, Arizona, 85054, United States
-
Mays Cancer Center at University of Texas Health San Antonio
San Antonio, Texas, 78229, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.